These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27394665)

  • 21. Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
    Tong L; Yu W; Chen L; Selyutin O; Dwyer MP; Nair AG; Mazzola R; Kim JH; Sha D; Yin J; Ruck RT; Davies IW; Hu B; Zhong B; Hao J; Ji T; Zan S; Liu R; Agrawal S; Xia E; Curry S; McMonagle P; Bystol K; Lahser F; Carr D; Rokosz L; Ingravallo P; Chen S; Feng KI; Cartwright M; Asante-Appiah E; Kozlowski JA
    J Med Chem; 2017 Jan; 60(1):290-306. PubMed ID: 27808515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.
    Yu W; Hu B; Zhong B; Hao J; Lei Z; Agrawal S; Rokosz L; Liu R; Chen S; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2019 Mar; 29(5):700-706. PubMed ID: 30711390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a New Structural Class of Broadly Acting HCV Non-Nucleoside Inhibitors Leading to the Discovery of MK-8876.
    McComas CC; Palani A; Chang W; Holloway MK; Lesburg CA; Li P; Liverton N; Meinke PT; Olsen DB; Peng X; Soll RM; Ummat A; Wu J; Wu J; Zorn N; Ludmerer SW
    ChemMedChem; 2017 Sep; 12(17):1436-1448. PubMed ID: 28741898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
    J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study.
    Palladino C; Sánchez-Carrillo M; Mate-Cano I; Vázquez-Morón S; Jimenez-Sousa MÁ; Gutiérrez-Rivas M; Resino S; Briz V
    Sci Rep; 2017 Jun; 7(1):2892. PubMed ID: 28588311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi
    Link JO; Taylor JG; Trejo-Martin A; Kato D; Katana AA; Krygowski ES; Yang ZY; Zipfel S; Cottell JJ; Bacon EM; Tran CV; Yang CY; Wang Y; Wang KW; Zhao G; Cheng G; Tian Y; Gong R; Lee YJ; Yu M; Gorman E; Mogalian E; Perry JK
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2415-2427. PubMed ID: 31230974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.
    Dwyer MP; Keertikar KM; Chen L; Tong L; Selyutin O; Nair AG; Yu W; Zhou G; Lavey BJ; Yang DY; Wong M; Kim SH; Coburn CA; Rosenblum SB; Zeng Q; Jiang Y; Shankar BB; Rizvi R; Nomeir AA; Liu R; Agrawal S; Xia E; Kong R; Zhai Y; Ingravallo P; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4106-11. PubMed ID: 27423481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent bisimidazole-based HCV NS5A inhibitors bearing annulated tricyclic motifs.
    Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5738-5742. PubMed ID: 25453811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.
    Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer M; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1954-1957. PubMed ID: 29653894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides.
    St Laurent DR; Belema M; Gao M; Goodrich J; Kakarla R; Knipe JO; Lemm JA; Liu M; Lopez OD; Nguyen VN; Nower PT; O'Boyle D; Qiu Y; Romine JL; Serrano-Wu MH; Sun JH; Valera L; Yang F; Yang X; Meanwell NA; Snyder LB
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6063-6. PubMed ID: 22959243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR
    Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.
    Giroux S; Bilimoria D; Cadilhac C; Cottrell KM; Denis F; Dietrich E; Ewing N; Henderson JA; L'Heureux L; Mani N; Morris M; Nicolas O; Reddy TJ; Selliah S; Shawgo RS; Xu J; Chauret N; Berlioz-Seux F; Chan LC; Das SK; Grillot AL; Bennani YL; Maxwell JP
    Bioorg Med Chem Lett; 2015 Feb; 25(4):940-3. PubMed ID: 25597006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores.
    Henderson JA; Bilimoria D; Bubenik M; Cadilhac C; Cottrell KM; Denis F; Dietrich E; Ewing N; Falardeau G; Giroux S; L'Heureux L; Liu B; Mani N; Morris M; Nicolas O; Pereira OZ; Poisson C; Reddy TJ; Selliah S; Shawgo RS; Vaillancourt L; Wang J; Xu J; Chauret N; Berlioz-Seux F; Chan LC; Das SK; Grillot AL; Bennani YL; Maxwell JP
    Bioorg Med Chem Lett; 2015 Feb; 25(4):948-51. PubMed ID: 25577039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.
    Liu R; Curry S; McMonagle P; Yeh WW; Ludmerer SW; Jumes PA; Marshall WL; Kong S; Ingravallo P; Black S; Pak I; DiNubile MJ; Howe AY
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6922-9. PubMed ID: 26303801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
    Scheel TK; Gottwein JM; Mikkelsen LS; Jensen TB; Bukh J
    Gastroenterology; 2011 Mar; 140(3):1032-42. PubMed ID: 21111742
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Asante-Appiah E; Liu R; Curry S; McMonagle P; Agrawal S; Carr D; Rokosz L; Lahser F; Bystol K; Chase R; Black S; Ferrari E; Ingravallo P; Tong L; Yu W; Kozlowski J
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel benzidine and diaminofluorene prolinamide derivatives as potent hepatitis C virus NS5A inhibitors.
    Bae IH; Kim HS; You Y; Chough C; Choe W; Seon MK; Lee SG; Keum G; Jang SK; Moon Kim B
    Eur J Med Chem; 2015 Aug; 101():163-78. PubMed ID: 26134551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.
    Hernandez D; Zhou N; Ueland J; Monikowski A; McPhee F
    J Clin Virol; 2013 May; 57(1):13-8. PubMed ID: 23384816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.
    Ramdas V; Talwar R; Banerjee M; Joshi AA; Das AK; Walke DS; Borhade P; Dhayagude U; Loriya R; Gote G; Bommakanti A; Sivaram A; Agarwal G; Goswami A; Nigade P; Mehta M; Patil V; Modi D; Kumar H; Mallurwar S; Dash A; Modi F; Kuldharan S; Srivastava P; Singh M; Narasimham L; Gundu J; Sharma S; Kamboj RK; Palle VP
    J Med Chem; 2019 Dec; 62(23):10563-10582. PubMed ID: 31710479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.